Clinical trials: Borderline Ovarian Tumors
Ovarian Neoplasms
KOrean Borderline Ovarian Tumor (KOBOT) Registry
The aim of this study is to collect data on Korean patients with borderline ovarian tumors.
- Trial name
- KOBOT (NCT02803970)
- Where
- 4 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Kangbuk Samsung Hospital
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Hysterectomy
Role of Hysterectomy in the Treatment of Borderline Ovarian Tumors
Borderline ovarian tumors (BOT), are rare epithelial ovarian tumors characterized by the presence of frankly malignant cytologic features in the absence of stromal invasion.
- Trial name
- NCT06825468
- Where
- 3 sites in Italy
- Volunteers
- 168 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor
Collecting Tumor Samples From Patients With Gynecological Tumors
This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in…
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
- Trial name
- NCT00897442
- Testing
- Laboratory Biomarker Analysis
- Where
- 187 sites in United States
- Volunteers
- 275 people
- Sponsor
- Gynecologic Oncology Group
Epithelial Ovarian Cancer, Epithelial Ovarian Tumor of Borderline Malignancy
A Genomic Analysis of Evolution of Epithelia Ovarian Tumors
Epithelial ovarian carcinomatous and borderline components sometimes appeared in one patient. This study aims to analyze the genomic patterns of the carcinomatous and borderline components in the ovarian epithelial tissues.
- Conditions
- Epithelial Ovarian Cancer, Epithelial Ovarian Tumor of Borderline Malignancy, Driving Mutations, Progression-free Survival
- Trial name
- NCT03742388
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Lei Li
Fallopian Tube Cancer, Ovarian Cancer
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to determine the effectiveness of imatinib mesylate in treating patients who have…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00039585
- Testing
- imatinib mesylate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)